Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 60,640 shares of the stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $27.21, for a total transaction of $1,650,014.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Exelixis, Inc. (NASDAQ EXEL) traded up 1.21% during midday trading on Friday, reaching $27.57. 8,048,436 shares of the company’s stock were exchanged. The stock has a market cap of $8.10 billion, a PE ratio of 139.24 and a beta of 1.97. Exelixis, Inc. has a 12-month low of $10.04 and a 12-month high of $29.50. The stock’s 50 day moving average is $27.05 and its 200-day moving average is $23.36.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The business had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $85.27 million. During the same quarter in the previous year, the business posted ($0.15) earnings per share. The business’s revenue was up 173.1% compared to the same quarter last year. On average, equities analysts expect that Exelixis, Inc. will post $0.27 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/15/patrick-j-haley-sells-60640-shares-of-exelixis-inc-exel-stock.html.

A number of hedge funds have recently bought and sold shares of EXEL. BlackRock Inc. increased its position in Exelixis by 33,678.5% during the first quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock valued at $415,099,000 after acquiring an additional 19,098,757 shares during the last quarter. Vanguard Group Inc. increased its position in Exelixis by 12.8% during the first quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock valued at $514,339,000 after acquiring an additional 2,696,877 shares during the last quarter. Matrix Capital Management Company LP increased its position in Exelixis by 8.8% during the second quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after acquiring an additional 1,225,000 shares during the last quarter. Janus Henderson Group PLC bought a new position in Exelixis during the second quarter valued at $28,689,000. Finally, Meditor Group Ltd increased its position in Exelixis by 5.5% during the second quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock valued at $498,258,000 after acquiring an additional 1,046,000 shares during the last quarter. Institutional investors and hedge funds own 79.20% of the company’s stock.

EXEL has been the topic of several recent research reports. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Cowen and Company reaffirmed an “outperform” rating on shares of Exelixis in a report on Thursday, August 10th. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 target price on the stock in a report on Tuesday, July 4th. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a report on Thursday, July 27th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $26.00 target price on shares of Exelixis in a report on Thursday, September 7th. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $26.51.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.